Filtered By:
Specialty: Cardiology
Cancer: Oral Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 85 results found since Jan 2013.
Association of type of oral anticoagulation with risk of bleeding in 45,114 patients with venous thromboembolism during initial and extended treatment-A nationwide register-based study
CONCLUSION: Apixaban had a lower bleeding risk than warfarin or rivaroxaban during initial treatment. During extended treatment, bleeding risk was similar for apixaban and rivaroxaban, and higher with warfarin.PMID:37641391 | DOI:10.1111/joim.13712
Source: Atherosclerosis - August 29, 2023 Category: Cardiology Authors: Katarina Glise Sandblad Sam Schulman Annika Rosengren Jan S örbo Jacob Philipson Per-Olof Hansson Source Type: research
Sulforaphane Inhibits Foam Cell Formation and Atherosclerosis via Mechanisms Involving the Modulation of Macrophage Cholesterol Transport and the Related Phenotype
In this study, in high fat diet fed ApoE-deficient (ApoE-/-) mice, oral SFN treatment improved dyslipidemia and inhibited atherosclerotic plaque formation and the unstable phenotype, as demonstrated by reductions in the lesion areas in both the aortic sinus and whole aorta, percentages of necrotic cores, vascular macrophage infiltration and reactive oxygen species (ROS) generation. In THP-1-derived macrophages, preadministration SFN alleviated oxidized low-density lipoprotein (ox-LDL)-induced lipid accumulation, oxidative stress and mitochondrial injury. Moreover, a functional study revealed that peritoneal macrophages iso...
Source: Atherosclerosis - July 11, 2023 Category: Cardiology Authors: Shiyan Liu Yuan Zhang Xiangyu Zheng Ziling Wang Pan Wang Mengdi Zhang Mengfan Shen Yongping Bao Dan Li Source Type: research
Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction
Oncologist. 2023 May 12:oyad116. doi: 10.1093/oncolo/oyad116. Online ahead of print.ABSTRACTCancer-associated thrombosis, with the incidence rising over the years, is associated with significant morbidity and mortality in patients with cancer. Recent advances in the treatment of cancer-associated venous thromboembolism (VTE) include the introduction of direct oral anticoagulants (DOACs), which provide a more convenient and effective option than low-molecular-weight heparin (LMWH). Nonetheless, important unmet needs remain including an increased risk of bleeding in certain patient subgroups such as those with gastroesophage...
Source: Atherosclerosis - May 12, 2023 Category: Cardiology Authors: Tzu-Fei Wang Alok A Khorana Giancarlo Agnelli Dan Bloomfield Marc P Bonaca Harry R B üller Jean M Connors Shinya Goto Zhi-Cheng Jing Ajay K Kakkar Yasser Khder Gary E Raskob Gerald A Soff Peter Verhamme Jeffrey I Weitz Marc Carrier Source Type: research
Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism
Arterioscler Thromb Vasc Biol. 2023 May 4. doi: 10.1161/ATVBAHA.123.318779. Online ahead of print.ABSTRACTPatients with cancer are at higher risk of developing venous thromboembolism (VTE) compared with the general population. This elevated risk is due to several risk factors and multiple, overlapping thrombotic and hemostatic pathophysiological pathways that are specific to this patient population. Hence, the management of cancer-associated VTE can be challenging for clinicians. Patients with cancer-associated VTE are at higher risk of both recurrent events despite anticoagulation and bleeding complications due to the ant...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - May 4, 2023 Category: Cardiology Authors: Laura Girardi Tzu-Fei Wang Walter Ageno Marc Carrier Source Type: research
Fullerene C < sub > 60 < /sub > Attenuates Heart Tissue Inflammation by Modulating COX-2 and TNF-Alpha Signaling Pathways in DMBA Induced Breast Cancer in Rats
Cardiovasc Toxicol. 2023 Jan 27. doi: 10.1007/s12012-023-09780-y. Online ahead of print.ABSTRACTThe present study aimed to investigate the therapeutic effect of fullerene C60 nanoparticle against heart tissue damage caused by 7,12-dimethylbenz [a] anthracene (DMBA) in female rats. Female Wistar albino rats, 8 weeks old (n = 60) weighing around (150 ± 10 g) were used for the study. These rats were divided into 4 groups and each group included 15 rats. Groups: (i) Control Group: Fed with standard diet; (ii) C60 Group: C60 (1.7 mg/kg bw, oral gavage); (iii) DMBA Group: DMBA (45 mg/kg bw, oral gavage); (iv) C60 and DMBA Group...
Source: Cardiovascular Toxicology - January 27, 2023 Category: Cardiology Authors: Seda Beyaz Abdullah Aslan Ozlem Gok Can Ali Agca Ibrahim Hanifi Ozercan Source Type: research
